BioCentury | Jun 11, 2001
Company News

ID Biomedical other research news

...IDBE's Intellivax International subsidiary will receive C$5.9 million (US$3.8 million) in funding from Technology Partnership Canada...
BioCentury | May 21, 2001
Company News

ID Biomedical, Intellivax deal

...IDBE completed its stock acquisition of Intellivax, a developer of influenza vaccines, for 4 million shares...
...2, 2001). IDBE has 25.6 million shares outstanding. ID Biomedical Corp. (IDBE; TSE:IDB), Burnaby, B.C. Intellivax International Inc....
BioCentury | May 21, 2001
Company News

ID Biomedical management update

...CSO of Intellivax International Inc. ; David Burt as VP of research, formerly VP of research at Intellivax...
...Gregory White as VP of process development, formerly VP of development and quality systems at Intellivax...
...Fries as VP of clinical and regulatory affairs, formerly VP of clinical and regulatory at Intellivax WIR...
BioCentury | Apr 30, 2001
Clinical News

Proteosome influenza vaccine: Phase I

...system and adjuvant Indication: Prevent influenza infection End point: Safety and immunogenicity Status: Phase I Intellivax...
...circulating hemagglutinin-specific antibodies. Data were presented at the Conference on Vaccine Research in Arlington, Va. Intellivax...
BioCentury | Apr 2, 2001
Company News

ID Biomedical, Intellivax deal

...IDBE will acquire intranasal vaccines developer Intellivax for 4 million shares, or about $12.1 million using...
...for 4 million shares, or about $12.1 million using IDBE's Friday closing price of $3.03. Intellivax...
...trials of its intranasal subunit vaccine to prevent influenza, with results expected later this year. Intellivax...
BioCentury | Mar 27, 2001
Company News

ID Biomed to acquire Intellivax

...ID Biomedical (IDBE; TSE:IDB) will acquire intranasal vaccines developer Intellivax for 4 million shares, or about...
...4 million shares, or about $12.5 million using IDBE's Tuesday morning NASDAQ price of $3.125. Intellivax...
...trials of its intranasal subunit vaccine to prevent influenza, with results expected later this year. Intellivax...
BioCentury | Dec 11, 2000
Company News

Cytran management update

...Inc., Kirkland, Wash. Business: Cancer Hired: William Milligan as president and COO, formerly CEO of Intellivax International Inc....
BioCentury | Dec 6, 2000
Company News

Cytran names president and COO

...COO, replacing Gene Larson, who will remain on the board. Milligan was formerly CEO of Intellivax...
BioCentury | Oct 16, 2000
Clinical News

Proteosome influenza vaccine: Began Phase I testing

...vaccine formulated with proteosome (protein microparticle) delivery system and adjuvant Indication: Prevent influenza infection Status: Intellivax...
BioCentury | Jun 5, 2000
Company News

Active Biotech, Intellivax deal

...Intellivax's proteosome delivery platform with ACTI's GAS antigen. Active Biotech AB (SSE:ACTI B), Lund, Sweden Intellivax International Inc....
Items per page:
1 - 10 of 10
BioCentury | Jun 11, 2001
Company News

ID Biomedical other research news

...IDBE's Intellivax International subsidiary will receive C$5.9 million (US$3.8 million) in funding from Technology Partnership Canada...
BioCentury | May 21, 2001
Company News

ID Biomedical, Intellivax deal

...IDBE completed its stock acquisition of Intellivax, a developer of influenza vaccines, for 4 million shares...
...2, 2001). IDBE has 25.6 million shares outstanding. ID Biomedical Corp. (IDBE; TSE:IDB), Burnaby, B.C. Intellivax International Inc....
BioCentury | May 21, 2001
Company News

ID Biomedical management update

...CSO of Intellivax International Inc. ; David Burt as VP of research, formerly VP of research at Intellivax...
...Gregory White as VP of process development, formerly VP of development and quality systems at Intellivax...
...Fries as VP of clinical and regulatory affairs, formerly VP of clinical and regulatory at Intellivax WIR...
BioCentury | Apr 30, 2001
Clinical News

Proteosome influenza vaccine: Phase I

...system and adjuvant Indication: Prevent influenza infection End point: Safety and immunogenicity Status: Phase I Intellivax...
...circulating hemagglutinin-specific antibodies. Data were presented at the Conference on Vaccine Research in Arlington, Va. Intellivax...
BioCentury | Apr 2, 2001
Company News

ID Biomedical, Intellivax deal

...IDBE will acquire intranasal vaccines developer Intellivax for 4 million shares, or about $12.1 million using...
...for 4 million shares, or about $12.1 million using IDBE's Friday closing price of $3.03. Intellivax...
...trials of its intranasal subunit vaccine to prevent influenza, with results expected later this year. Intellivax...
BioCentury | Mar 27, 2001
Company News

ID Biomed to acquire Intellivax

...ID Biomedical (IDBE; TSE:IDB) will acquire intranasal vaccines developer Intellivax for 4 million shares, or about...
...4 million shares, or about $12.5 million using IDBE's Tuesday morning NASDAQ price of $3.125. Intellivax...
...trials of its intranasal subunit vaccine to prevent influenza, with results expected later this year. Intellivax...
BioCentury | Dec 11, 2000
Company News

Cytran management update

...Inc., Kirkland, Wash. Business: Cancer Hired: William Milligan as president and COO, formerly CEO of Intellivax International Inc....
BioCentury | Dec 6, 2000
Company News

Cytran names president and COO

...COO, replacing Gene Larson, who will remain on the board. Milligan was formerly CEO of Intellivax...
BioCentury | Oct 16, 2000
Clinical News

Proteosome influenza vaccine: Began Phase I testing

...vaccine formulated with proteosome (protein microparticle) delivery system and adjuvant Indication: Prevent influenza infection Status: Intellivax...
BioCentury | Jun 5, 2000
Company News

Active Biotech, Intellivax deal

...Intellivax's proteosome delivery platform with ACTI's GAS antigen. Active Biotech AB (SSE:ACTI B), Lund, Sweden Intellivax International Inc....
Items per page:
1 - 10 of 10